This is an exciting addition to my recent interview with Accellta’s CEO, Dr. Itzchak Angel, who highlighted Accellta’s unique technologies for enabling large scale growth of cells in suspension. This interview features insights from Eran Cohen, Accellta’s head of business development and intellectual property (IP) officer.
I am frequently surprised by how often people misuse the terms “neural” and “neuronal” when speaking about stem cells. Admittedly, the differences are subtle, but they are extremely important. In an effort to clarify terminology, this article explains and defines a range of neural stem cell (NSC) terms. [Read more…]
Montreal, Canada, May 4, 2017 – Fortuna Fix Inc., (“Fortuna”), a private, clinical-stage biotech company is aiming to be the first to eliminate the need for embryonic and fetal stem cells by using direct reprogramming of autologous cells to treat neurodegenerative diseases. Fortuna announced today the launch of its Scientific Advisory Board (“SAB”) with Professor Michael Fehlings, MD, PhD, Father Kevin FitzGerald, S.J., PhD, COL (R) Dallas Hack, MD, MPH, and Professor James Giordano, PhD. [Read more…]
“Stem Cell Research Products – Opportunities, Tools, & Technologies” is a global strategic report report that evaluates opportunities across the entire stem cell product spectrum, with emphasis on opportunities for research product development. [Read more…]
What do we know of the safety and efficacy of stem cell therapeutics?
Over 50 years have passed since the discovery of hematopoietic stem cells (bone marrow transplantation to cure diseases such as leukemia), almost 20 years since the discovery of human embryonic stem cells (hESC), and 10 years since the discovery of induced pluripotent stem cells (iPS cells). There are also more than 5,000 stem cell trials ongoing in clinics globally. Despite this experience, what do we actually know about the safety and efficacy of stem cell therapeutics?
In this novel and increasingly complex stem cell space, it is perhaps a timely question to ask, especially since the regulatory assessment criteria designed for conventional medicines are not directly applicable for stem cell therapy. [Read more…]